574711-99-2

Basic information

• Product Name: N-(3-chlorophenyl)-2-(4-formylphenoxy)acetamide
• Synonyms: N-(3-chlorophenyl)-2-(4-formylphenoxy)acetamide;Acetamide, N-(3-chlorophenyl)-2-(4-formylphenoxy)-
• CAS NO: 574711-99-2
• Molecular Formula: C₁₅H₁₂ClNO₃
• Molecular Weight: 289.71
• Mol File: 574711-99-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3-chlorophenyl)-2-(4-formylphenoxy)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-chlorophenyl)-2-(4-formylphenoxy)acetamide(574711-99-2)
• EPA Substance Registry System: N-(3-chlorophenyl)-2-(4-formylphenoxy)acetamide(574711-99-2)

Safety Data

• Hazardous Substances Data: 574711-99-2(Hazardous Substances Data)

Upstream product

• 41964-65-2 2-bromo-N-(3-chlorophenyl)acetamide 
• 123-08-0 4-hydroxy-benzaldehyde 
• 17641-03-1 N-(3-chlorophenyl)-2-iodoacetamide 
• 2564-05-8 2-chloro-N-(3-chlorophenyl)acetamide 
• 108-42-9 3-chloro-aniline 

Relevant articles and documents

Chitosan and functionalized graphene oxide nanocomposite as a novel and highly efficient catalyst for production of bis-coumarins under solvent-free conditions

Chitosan and functionalized graphene oxide nanocomposite was used as efficient, sustainable, and recyclable catalyst in the production of bis-coumarins using 4-hydroxycoumarin and aromatic aldehydes under solvent-free conditions. Chitosan was first functi

Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy

Inhibition of cyclin dependent kinase 4 (Cdk4) prevents cancer cells from entering the early G0/G1 phase of the cell division cycle whereas inhibiting tubulin polymerization blocks cancer cells’ ability to undergo mitosis (M) late in the cell cycle. We had reported earlier that two non-planar and relatively non-toxic fascaplysin derivatives, an indole and a tryptoline, inhibit Cdk4 with IC50 values of 6.2 and 10 μM, respectively. Serendipitously, we had also found that they inhibited tubulin polymerization. The molecules were efficacious in mouse tumor models. We have now identified Cink4T in a 59-compound quinazolinone library, designed on the basis of ligand-based virtual screening, as a compound that inhibits Cdk4 and tubulin. Its IC50 value for Cdk4 inhibition is 0.47 μM and >50 μM for inhibition of Cdk1, Cdk2, Cdk6, Cdk9. Cink4T inhibits tubulin polymerization with an IC50 of 0.6 μM. Molecular modelling studies on Cink4T with Cdk4 and tubulin crystal structures lend support to these observations. Cancer cell cycle analyses confirm that Cink4T blocks cells at both G0/G1 and M phases as it should if it were to inhibit both Cdk4 and tubulin polymerization. Our results show, for the very first time, that virtual screening can be used to design novel inhibitors that can potently block two crucial phases of the cell division cycle.

Structural exploration, synthesis and pharmacological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives as iNOS inhibitors against inflammatory diseases

In our previous work, 3I inhibited the LPS-induced iNOS activity and NO production in RAW 264.7 cells and improved joint inflammation and cartilage destruction in inflammatory model. In this study, we synthesized 59 derivatives and bioisosteres on the bas